{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:44:56Z","timestamp":1792784696290,"version":"4.5.0"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"19","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["S202510316033"],"award-info":[{"award-number":["S202510316033"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20210422"],"award-info":[{"award-number":["BK20210422"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20242075"],"award-info":[{"award-number":["BK20242075"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632023TD07"],"award-info":[{"award-number":["2632023TD07"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2632024ZD05"],"award-info":[{"award-number":["2632024ZD05"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["82103989"],"award-info":[{"award-number":["82103989"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["82104030"],"award-info":[{"award-number":["82104030"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["82273968"],"award-info":[{"award-number":["82273968"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC)","award":["82473966"],"award-info":[{"award-number":["82473966"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Youth Science and Technology Talent Support Program of Jiangsu Province","award":["JSTJ-2024-110"],"award-info":[{"award-number":["JSTJ-2024-110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glutaminase 1 (GLS1) and histone deacetylases (HDACs) are important targets involved in cancer metabolism and epigenetic regulation, respectively. Herein, we report the design, synthesis, and biological evaluation of first-in-class GLS1\/HDAC dual inhibitors as a single-molecule strategy for cancer therapy. Through systematic structure-activity relationship studies and biochemical profiling, compound 58 was identified as a promising dual inhibitor with moderate GLS1 inhibition and potent HDAC activity, particularly against HDAC6. Compound 58 exhibited strong antiproliferative activity in multiple cancer cell lines and modulated GLS1-associated glutamine metabolism and HDAC-related acetylation markers in cells. In a CT26 tumor-bearing mouse model, compound 58 achieved a tumor growth inhibition (TGI) rate of 91.10% without obvious systemic toxicity. Overall, this study supports GLS1\/HDAC dual inhibition as a promising anticancer strategy and provides compound 58 as a valuable lead for further optimization.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01288","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:01:54Z","timestamp":1790182914000},"page":"22138-22161","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy"],"prefix":"10.1021","volume":"69","author":[{"given":"Zhisheng","family":"Zhang","sequence":"first","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinan","family":"Jiang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Nanjing University of Chinese Medicine , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Li","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Yang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Shi","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Cao","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiang","family":"Jiang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Tian","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Ru","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuxiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Du","sequence":"additional","affiliation":[{"name":"Nanjing Medical University , , ,","place":["Nanjing, P. R. China, 210006"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-1195","authenticated-orcid":true,"given":"Jinlei","family":"Bian","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-9511","authenticated-orcid":true,"given":"Zhiyu","family":"Li","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-7373","authenticated-orcid":true,"given":"Xi","family":"Xu","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jubo","family":"Wang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026100811114853300_cit1","doi-asserted-by":"publisher","first-page":"108523","DOI":"10.1016\/j.bioorg.2025.108523","article-title":"Deciphering the Landscape of Allosteric Glutaminase 1 Inhibitors as Anticancer Agents","volume":"161","author":"Vagaggini","year":"2025","journal-title":"Bioorg. Chem."},{"key":"2026100811114853300_cit2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2019.09.011","article-title":"Dysregulation of Glutaminase and Glutamine Synthetase in Cancer","volume":"467","author":"Mate\u0301s","year":"2019","journal-title":"Cancer Lett."},{"issue":"9","key":"2026100811114853300_cit3","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1158\/0008-5472.can-14-3745","article-title":"Amino Acid Transporters in Cancer and Their Relevance to \u201cGlutamine Addiction\u201d: Novel Targets for the Design of a New Class of Anticancer Drugs","volume":"75","author":"Bhutia","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"2026100811114853300_cit4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1021\/acs.jmedchem.8b00961","article-title":"Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions","volume":"62","author":"Xu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026100811114853300_cit5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s11064-017-2212-1","article-title":"Glutamine Addiction in Gliomas","volume":"42","author":"Ma\u0301rquez","year":"2017","journal-title":"Neurochem. Res."},{"issue":"1","key":"2026100811114853300_cit6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12672-025-02790-y","article-title":"Glutamate Promotes Triple-Negative Breast Cancer Development through IRE1\u03b1\/XBP1-Mediated Macrophage Polarization: Mechanism Insights and Therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Discover Oncol."},{"issue":"18","key":"2026100811114853300_cit7","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1021\/acs.jmedchem.6b01069","article-title":"Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma","volume":"59","author":"Rais","year":"2016","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026100811114853300_cit8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1042\/bj20070039","article-title":"Novel Mechanism of Inhibition of Rat Kidney-Type Glutaminase by Bis-2-(5-Phenylacetamido-1,2,4-Thiadiazol-2-Yl)Ethyl Sulfide (BPTES)","volume":"406","author":"Robinson","year":"2007","journal-title":"Biochem. J."},{"issue":"4","key":"2026100811114853300_cit9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.mct-13-0870","article-title":"Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"2026100811114853300_cit10","doi-asserted-by":"publisher","first-page":"129266","DOI":"10.1016\/j.bmcl.2023.129266","article-title":"Design, Synthesis, Structure\u2212Activity Relationship Studies, and Evaluation of Novel GLS1 Inhibitors","volume":"87","author":"Jo","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"23","key":"2026100811114853300_cit11","doi-asserted-by":"publisher","first-page":"10551","DOI":"10.1021\/jm301191p","article-title":"Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-Phenylacetamido-1,2,4-Thiadiazol-2-Yl)Ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors","volume":"55","author":"Shukla","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026100811114853300_cit12","unstructured":"Di Francesco, M. E.; Jones, P.; Heffernan, T.; Hamilton, M.; Kang, Z.; Soth, M. P.; Burke, J. P.; Le, K.; Carroll, C. L.; Palmer, W.; Lewis, R.; McAfoos, T.; Czako, B.; Liu, G.; Theroff, J.; Herrera, Z.; Yau, A.\n          GLS1 Inhibitors for Treating Disease. WO 2016004404 A2, 2016."},{"issue":"21","key":"2026100811114853300_cit13","doi-asserted-by":"publisher","first-page":"12957","DOI":"10.1021\/acs.jmedchem.0c01398","article-title":"Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties","volume":"63","author":"Soth","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026100811114853300_cit14","doi-asserted-by":"publisher","first-page":"115014","DOI":"10.1016\/j.ejmech.2022.115014","article-title":"Design, Synthesis, and Biological Evaluation of Novel Glutaminase 1 Allosteric Inhibitors with an Alkane Chain Tail Group","volume":"246","author":"Chang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"2026100811114853300_cit15","doi-asserted-by":"publisher","first-page":"114337","DOI":"10.1016\/j.ejmech.2022.114337","article-title":"Discovery of Novel Glutaminase 1 Allosteric Inhibitor with 4-Piperidinamine Linker and Aromatic Heterocycles","volume":"236","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2026100811114853300_cit16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/1535-7163.mct-20-0430","article-title":"The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell\u2212Mediated Immunotherapies","volume":"20","author":"Varghese","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"2026100811114853300_cit17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-02119-1","article-title":"Identification of Glutamine as a Potential Therapeutic Target in Dry Eye Disease","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduction Targeted Ther."},{"issue":"1\u22122","key":"2026100811114853300_cit18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-Target Therapeutics: When the Whole Is Greater than the Sum of the Parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discovery Today"},{"issue":"11","key":"2026100811114853300_cit19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network Pharmacology: The Next Paradigm in Drug Discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"2026100811114853300_cit20","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1021\/acs.jmedchem.4c01787","article-title":"Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1\u22122","key":"2026100811114853300_cit21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drudis.2011.08.002","article-title":"The Role of Fragment-Based and Computational Methods in Polypharmacology","volume":"17","author":"Bottegoni","year":"2012","journal-title":"Drug Discovery Today"},{"issue":"21","key":"2026100811114853300_cit22","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed Multiple Ligands. An Emerging Drug Discovery Paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026100811114853300_cit23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam Med. J."},{"issue":"6749","key":"2026100811114853300_cit24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","article-title":"Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors","volume":"401","author":"Finnin","year":"1999","journal-title":"Nat."},{"issue":"4","key":"2026100811114853300_cit25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/21541264.2017.1394423","article-title":"A Role for Histone Acetylation in Regulating Transcription Elongation","volume":"9","author":"Church","year":"2018","journal-title":"Transcription"},{"issue":"2","key":"2026100811114853300_cit26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0959-437x(00)00173-8","article-title":"Histone Acetyltransferases: Function, Structure, and Catalysis","volume":"11","author":"Marmorstein","year":"2001","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"3","key":"2026100811114853300_cit27","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1021\/acs.jmedchem.8b01825","article-title":"Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy","volume":"62","author":"Chen","year":"2019","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026100811114853300_cit28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1021\/acs.jmedchem.7b01465","article-title":"Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026100811114853300_cit29","doi-asserted-by":"publisher","first-page":"112904","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive Review for Anticancer Hybridized Multitargeting HDAC Inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"2026100811114853300_cit30","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","article-title":"Early Phase II Trial of Oral Vorinostat in Relapsed or Refractory Breast, Colorectal, or Non-Small Cell Lung Cancer","volume":"26","author":"Vansteenkiste","year":"2008","journal-title":"Invest. New Drugs"},{"issue":"24","key":"2026100811114853300_cit31","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1158\/1078-0432.ccr-07-2114","article-title":"Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications","volume":"13","author":"Fantin","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"2026100811114853300_cit32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.105","article-title":"ROS Homeostasis and Metabolism: A Dangerous Liaison in Cancer Cells","volume":"7","author":"Panieri","year":"2016","journal-title":"Cell Death Dis."},{"issue":"12","key":"2026100811114853300_cit33","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948375","article-title":"Class I HDAC Inhibitors Enhance YB-1 Acetylation and Oxidative Stress to Block Sarcoma Metastasis","volume":"20","author":"El-Naggar","year":"2019","journal-title":"EMBO Rep."},{"issue":"34","key":"2026100811114853300_cit34","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1038\/onc.2017.103","article-title":"Metabolic Inhibitors Accentuate the Antitumoral Effect of HDAC5 inhibition","volume":"36","author":"Hendrick","year":"2017","journal-title":"Oncogene"},{"key":"2026100811114853300_cit35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.20517\/cdr.2024.35","article-title":"Inhibition of Glutaminolysis Alone and in Combination with HDAC Inhibitor Has Anti-Myeloma Therapeutic Effects","volume":"7","author":"Okabe","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"2026100811114853300_cit36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bioactmat.2022.08.006","article-title":"HDAC I\/IIb Selective Inhibitor Purinostat Mesylate Combined with GLS1 Inhibition Effectively Eliminates CML Stem Cells","volume":"21","author":"Qiu","year":"2023","journal-title":"Bioact. Mater."},{"issue":"21","key":"2026100811114853300_cit37","doi-asserted-by":"publisher","first-page":"22959","DOI":"10.1021\/acs.jmedchem.5c01841","article-title":"Design, Synthesis, and Biological Evaluation of Rapamycin Derivatives as the First Mammalian Target of Rapamycin and GLS1 Dual Inhibitors","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026100811114853300_cit38","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2412.12032","article-title":"Inhibition of GLS1 and ASCT2 Synergistically Enhances the Anticancer Effects in Pancreatic Cancer Cells","volume":"35","author":"Kim","year":"2025","journal-title":"J. Microbiol. Biotechnol."},{"issue":"6","key":"2026100811114853300_cit39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/187152009788679976","article-title":"Histone Deacetylase Inhibitors: Design, Structure-activity Relationships and Therapeutic Implications for Cancer","volume":"9","author":"Marson","year":"2009","journal-title":"Anticancer Agents Med. Chem."},{"issue":"21","key":"2026100811114853300_cit40","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1016\/j.bmcl.2005.07.081","article-title":"Exploring the Connection Unit in the HDAC Inhibitor Pharmacophore Model: Novel Uracil-Based Hydroxamates","volume":"15","author":"Mai","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026100811114853300_cit41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejmech.2017.03.024","article-title":"Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Benzamides as Potent Histone Deacetylase Inhibitors and Anticancer Agents","volume":"132","author":"Abdizadeh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"2026100811114853300_cit42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in Cancer: Rationale and Strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"10","key":"2026100811114853300_cit43","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.molcel.2022.03.016","article-title":"Filamentous GLS1 Promotes ROS-Induced Apoptosis upon Glutamine Deprivation via Insufficient Asparagine Synthesis","volume":"82","author":"Jiang","year":"2022","journal-title":"Mol. Cell"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01288","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22138\/68625222\/jm6c01288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22138\/68625222\/jm6c01288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:32:57Z","timestamp":1791473577000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/19\/22138\/5436871\/Discovery-of-Novel-Glutaminase-GLS1-and-Histone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":43,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01288","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}